Skip to main content
. 2019 Dec 10;8(4):CNS47. doi: 10.2217/cns-2019-0017

Table 1. . Patient characteristics by treatment regimen.

Patient characteristics All patients Chemotherapy and radiotherapy Chemotherapy only Radiotherapy only Supportive treatment
Number 210 67 (31.9) 16 (7.6) 23 (11.0) 104 (49.5)
Mean age (SD) 74.2 (6.29) 69.8 (4.0) 72.5 (6.1) 72.5 (6.0) 76.8 (6.0)
Age group (years):
  – 65–<70
  – 70–<75
  – 75+
71 (33.8)
50 (23.8)
89 (42.4)
40 (59.7)
18 (26.9)
9 (13.4)
7 (43.8)
2 (12.5)
7 (43.8)
10 (43.5)
6 (26.1)
7 (30.4)
14 (13.5)
24 (23.1)
66 (63.5)
Sex:
  – Men
  – Women
118 (56.2)
92 (43.8)
35 (52.2)
32 (47.8)
8 (50.0)
8 (50.0)
14 (60.9)
9 (39.1)
61 (58.7)
43 (41.3)
Performance status:
  – 0
  – 1
  – 2
  – 3+
  – Unknown
23 (11.0)
73 (34.8)
41 (19.5)
61 (29.0)
12 (5.7)
17 (25.4)
31 (46.3)
9 (13.4)
5 (7.5)
5 (7.5)
1 (6.3)
12 (75.0)
2 (12.5)
1 (6.3)
0 (0.0)
2 (8.7)
9 (39.1)
7 (30.4)
3 (13.0)
2 (8.7)
3 (2.9)
21 (20.2)
23 (22.1)
52 (50.0)
5 (4.8)
Treatment center:
  – Glasgow
  – Brighton
  – Manchester
100 (47.6)
37 (17.6)
73 (34.8)
16 (23.9)
9 (13.4)
42 (62.7)
16 (100.0)
0 (0.0)
0 (0.0)
3 (13.0)
6 (26.1)
14 (60.9)
65 (62.5)
22 (21.2)
17 (16.3)
MGMT promoter methylation:
  – Tested
  – Methylated
  – Unmethylated
  – Failed testing
80
25 (31.3)
50 (62.5)
5 (6.3)
32
9 (28.1)
23 (71.9)
2 (6.3)
16
10 (62.5)
6 (37.5)
0 (0.0)
9
2 (22.2)
6 (66.7)
1 (11.1)
21
4 (19.0)
15 (71.4)
2 (9.5)
Neurosurgery:
  – Stereotactic biopsy
  – Subtotal resection <90%
  – Gross total resection >90%
  – Unknown surgery
  – No surgery
30 (14.3)
58 (27.6)
37 (17.6)
1 (4.8)
84 (40.0)
7 (10.4)
42 (62.7)
18 (26.9)
0 (0.0)
0 (0.0)
7 (43.8)
4 (25.0)
4 (25.0)
1 (6.3)
0 (0.0)
6 (26.1)
4 (17.4)
6 (26.1)
0 (0.0)
7 (30.4)
10 (9.6)
8 (7.7)
9 (8.7)
0 (0.0)
77 (74.0)
Diagnosis:
  – Pathological diagnosis
  – Radiological diagnosis
122 (58.1)
88 (41.9)
67 (100.0)
0 (0.0)
16 (100.0)
0 (0.0)
16 (69.6)
7 (30.4)
23 (22.1)
81 (77.9)

The numbers in brackets represent percentages unless indicated otherwise.

SD: Standard deviation.